CM
Crestline Management’s Biogen BIIB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-6,750
| Closed | -$1.31M | – | 729 |
|
|
2024
Q3 | $1.31M | Buy |
+6,750
| New | +$1.31M | 0.07% | 231 |
|
|
2022
Q3 | – | Sell |
-9,595
| Closed | -$1.96M | – | 214 |
|
|
2022
Q2 | $1.96M | Buy |
9,595
+3,689
| +62% | +$752K | 0.26% | 85 |
|
|
2022
Q1 | $1.24M | Buy |
5,906
+193
| +3% | +$40.7K | 0.15% | 123 |
|
|
2021
Q4 | $1.37M | Buy |
+5,713
| New | +$1.37M | 0.1% | 131 |
|
|
2021
Q3 | – | Sell |
-2,852
| Closed | -$988K | – | 226 |
|
|
2021
Q2 | $988K | Buy |
+2,852
| New | +$988K | 0.09% | 99 |
|
|
2017
Q4 | – | Sell |
-11,145
| Closed | -$3.49M | – | 162 |
|
|
2017
Q3 | $3.49M | Buy |
11,145
+1,602
| +17% | +$502K | 0.49% | 31 |
|
|
2017
Q2 | $2.59M | Buy |
+9,543
| New | +$2.59M | 0.35% | 27 |
|
|
2017
Q1 | – | Sell |
-5,832
| Closed | -$1.65M | – | 116 |
|
|
2016
Q4 | $1.65M | Buy |
5,832
+2,262
| +63% | +$642K | 0.41% | 14 |
|
|
2016
Q3 | $1.12M | Buy |
+3,570
| New | +$1.12M | 0.14% | 81 |
|